KH902对大鼠缝线法致眼角膜新生血管的治疗效果评价

Effect of KH902 in Inhibiting Suture Induced Corneal Neovascularization

目的评价复明肽(Fumintide,KH902)局部应用对缝线法致大鼠角膜新生血管(corneal neovascularization,CNV)的抑制作用。方法将60只成年健康大鼠利用缝线法建立CNV模型后采用随机数字表法分入3组:A组(n=20)为KH902治疗组(KH902 30mg/mL隔日球结膜下注射1次,0.025mL/次);B组(n=20)为地塞米松治疗组(0.1%地塞米松隔日球结膜下注射1次,0.025mL/次);C组(n=20)为空白对照组。分别于缝线术后3、7、14d裂隙灯显微镜下观察记录各组大鼠CNV长出的时间、CNV的长度和数量,并拍照。术后第14d开始给药,给药1、7、14及21d后观察CNV变化情况并记录。以免疫组织化学方法观察血管内皮生长因子(vascular endothelial growth factor,VEGF)的表达情况。结果用药1、7d后各组大鼠CNV面积两两比较差异无统计学意义;用药14、21d后,A组与B组CNV面积差异无统计学意义,但均低于C组CNV面积(P<0.01)。角膜基质中VEGF表达在角膜缝线术后14d达到高峰,用药后可见VEGF表达逐渐减少,且A组与B组效果相当。结论 KH902(30mg/mL)经球结膜下注射给药可使已形成的缝线法所致大鼠角膜CNV明显退缩,其作用与0.1%地塞米松球结膜下注射相比较差异无统计学意义。

Objective To evaluate the effect of topical KH902 on experimental corneal neovascularization （CNV） in rats. Methods Suture models of CNV were established in 60 adult healthy rats. The rats were randomly divided into 3 groups： Group A （20 rats） were treated with KH902 （KH902 30 mg/mL was injected subconjunctivally once every other day）; Group B （20 rats） were treated with dexamethasone （0. 1% dexamethasone was injected subconjunctivally once every other day）; Group C （20 rats） served as blank control. CNV growth were observed by slitlamp microscopy 3, 7 and 14 d after suture. Medicines were administered 14 d after operations. CNV changes were observed and recorded 1, 7, 14, and 21 d after administration of medicines. VEGF expression in cornea was measured by immunohistoehemistry. Results No significant differences were found in average areas of CNV between groups at 1 and 7 d after administration of medicines. At 14 and 21 d after administration of medicines, significant differences in average areas of CNV were found between Group A and Group C, and between Group B and Group C （P〈0.01）. Maximum expression of VEGF in corneal stroma was observed 14 d after corneal suture. The expression of VEGF decreased with medications, which was associated with neovascularization. Conclusion Topical use of KH902 inhibits corneal suture-induced CNV in rats without significant adverse corneal effect on eyes.